Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
#2
JOURNAL ARTICLE
Helen Burton-Murray, Katheryn Kiser, Jenny Gurung, Katherine Williams, Jennifer J Thomas, Hamed Khalili
BACKGROUND AND AIM: Recent studies have shown that up to 53% of patients with inflammatory bowel disease (IBD) screen positive for avoidant/restrictive food intake disorder (ARFID). There is however concern that ARFID screening rates are over-inflated in patients with active disease. We aimed to evaluate the frequency and characteristics of ARFID symptoms using the Nine Item ARFID Screen (NIAS), and to use another eating disorder measure, the Eating Disorder Examination-Questionnaire 8 (EDE-Q8), to rule-out/characterize other eating disorder cognitive and behavioral symptoms...
April 18, 2024: Journal of Crohn's & Colitis
#3
JOURNAL ARTICLE
Nicola J Wyatt, Hannah Watson, Carl A Anderson, Nicholas A Kennedy, Tim Raine, Tariq Ahmad, Dean Allerton, Michelle Bardgett, Emma Clark, Dawn Clewes, Cristina Cotobal Martin, Mary Doona, Jennifer A Doyle, Katherine Frith, Helen C Hancock, Ailsa L Hart, Victoria Hildreth, Peter M Irving, Sameena Iqbal, Ciara Kennedy, Andrew King, Sarah Lawrence, Charlie W Lees, Robert Lees, Laura Letchford, Trevor Liddle, James O Lindsay, Rebecca H Maier, John C Mansfield, Julian R Marchesi, Naomi McGregor, Rebecca E McIntyre, Jasmin Ostermayer, Tolulope Osunnuyi, Nick Powell, Natalie J Prescott, Jack Satsangi, Shriya Sharma, Tara Shrestha, Ally Speight, Michelle Strickland, James Ms Wason, Kevin Whelan, Ruth Wood, Gregory R Young, Xinyue Zhang, Miles Parkes, Christopher J Stewart, Luke Jostins-Dean, Christopher A Lamb
INTRODUCTION: Characterised by chronic inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can significantly impact patient's quality of life. Therapeutic developments in the last 20 years have revolutionised treatment. However, clinical trials and real-world data show primary non-response rates up to 40%. A significant challenge is an inability to predict which treatment will benefit individual patients...
April 17, 2024: BMJ Open
#4
JOURNAL ARTICLE
Morris Gordon, Jamal Khudr, Vassiliki Sinopoulou, Svetlana Lakunina, Aditi Rane, Anthony Akobeng
OBJECTIVE: Our objective was to perform a systemic evaluation of the risk of bias in randomised controlled trial (RCT) reports published on inflammatory bowel disease (IBD). DESIGN: We assessed the risk of bias using the Cochrane tool, as indicators of poor methodology or subsequently poor reporting. We systematically selected, with dual independent judgements, all studies published on IBD with no time limits and assessed the methodological quality of included studies again using independent dual ratings...
April 17, 2024: BMJ Open Gastroenterology
#5
JOURNAL ARTICLE
Laura Vekara, Saija Kantanen, Kaija-Leena Kolho, Kati Räsänen, Timo Lakka, Heini Huhtala, Eija Piippo-Savolainen, Pekka Arikoski, Pauliina Hiltunen
OBJECTIVES: Prior studies on the psychological well-being in pediatric inflammatory bowel disease (PIBD) have reported controversial results. Our aim was to compare the psychological well-being and lifestyle factors in patients with PIBD and their controls and to assess the role of contributing disease characteristics. METHODS: This cross-sectional study included 60 PIBD patients aged 6-17 years (26 with Crohn's disease [CD], 34 with ulcerative colitis [CD] or unclassified colitis [IBD-U]) from two university hospitals in Finland, and their age- and sex-matched healthy controls...
April 17, 2024: Journal of Pediatric Gastroenterology and Nutrition
#6
JOURNAL ARTICLE
Katja Tepeš, Jurij Hanžel, David Štubljar, Karin Strmšek, Luka Erjavec, Eva Supovec, Zala Jagodic, Mirjam Končan, Jan Grosek, Jurij Aleš Košir, Aleš Tomažič, Urška Kogovšek, Gregor Norčič, Renata Šibli, Marija Žnidaršič, Tadeja Pačnik Vižintin, Barbara Sodin, Janez Breznik, Vanesa Anderle Hribar, Andreja Ocepek, Cvetka Pernat Drobež, Nejc Bukovnik, Andrej Zafošnik, Tamara Marušič, Nataša Jurečič Brglez, Maja Denkovski, Nataša Smrekar, Gregor Novak, Matic Koželj, Tina Kurent, Jože Simonič, Špela Pintar, Borut Štabuc, David Drobne
BACKGROUND: With the increasing number of inflammatory bowel disease (IBD) patients, it is difficult to manage them within specialised IBD teams in academic medical centres: many are therefore treated in nonacademic IBD centres. It is unclear whether the time to introducing biologics is the same in both settings. AIM: We aimed to compare treatment approach with biologics in academic vs. nonacademic centres. METHODS: We analysed Slovenian national IBD registry data (UR-CARE Registry, supported by the European Crohn's and Colitis Organisation), which included 2 academic (2319 patients) and 4 nonacademic IBD (429 patients) centres...
April 2, 2024: European Journal of Gastroenterology & Hepatology
#7
EDITORIAL
Daniéla Oliveira Magro, Ligia Yukie Sassaki, Júlio Maria Fonseca Chebli
In this editorial, we comment on the article by Marangoni et al , published in the recent issue of the World Journal of Gastroenterology 2023; 29: 5618-5629, about "Diet as an epigenetic factor in inflammatory bowel disease". The authors emphasized the role of diet, especially the interaction with genetics, in promoting the inflammatory process in inflammatory bowel disease (IBD) patients, focusing on DNA methylation, histone modifications, and the influence of microRNAs. In this editorial, we explore the interaction between genetics, gut microbiota, and diet, in an only way...
March 28, 2024: World Journal of Gastroenterology: WJG
#8
JOURNAL ARTICLE
Kassem Sharif, Adi Lahat, Yonatan Shneor Patt, Niv Ben-Shabat, Mahmud Omar, Abdulla Watad, Howard Amital, Omer Gendelman
BACKGROUND: Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are chronic conditions with overlapping pathogenic mechanisms. The genetic predisposition and inflammatory pathways common to both diseases suggest a syndemic relationship. While some evidence points to a connection between the two conditions, other reports do not support this link. OBJECTIVES: To investigate the association between AS and the subsequent incidence of IBD. To identify potential risk factors and effect modifiers that contribute to this relationship...
April 2024: Israel Medical Association Journal: IMAJ
#9
JOURNAL ARTICLE
Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, Julian Panés, Stefan Schreiber, Walter Reinisch, Brian G Feagan, Silvio Danese, Andres J Yarur, Geert R D'Haens, Martina Goetsch, Karolina Wosik, Michael Keating, Krisztina Lazin, Joseph Wu, Irene Modesto, Aoibhinn McDonnell, Lauren Bartolome, Séverine Vermeire
BACKGROUND AND AIMS: Pivotal trials in ulcerative colitis have historically excluded patients with isolated proctitis. Etrasimod is an oral, oncedaily, selective sphingosine 1phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis. This post hoc analysis assessed efficacy and safety of etrasimod 2 mg once daily in patients with isolated proctitis (centrally read) from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. METHODS: Patients, including those with isolated proctitis (<10 cm rectal involvement) who met all other inclusion criteria in ELEVATE UC 52 and ELEVATE UC 12, were randomised 2:1 to receive etrasimod or placebo...
April 13, 2024: Journal of Crohn's & Colitis
#10
JOURNAL ARTICLE
Margaret Brown, Anne Dodd, Fang Shi, Emily Greenwood, Sini Nagpal, Vasantha L Kolachala, Subra Kugathasan, Greg Gibson
BACKGROUND AND AIMS: Crohn's disease is characterized by inflammation in the gastrointestinal tract due to a combination of genetic, immune, and environmental factors. Transcriptomic and epigenomic profiling of intestinal tissue of Crohn's disease patients have revealed valuable insights into pathology, however have not been conducted jointly on less invasive peripheral blood mononuclear cells (PBMCs). Furthermore, the heterogeneous responses to treatments among individuals with Crohn's disease imply hidden diversity of pathological mechanisms...
April 13, 2024: Journal of Crohn's & Colitis
#11
REVIEW
Javier Plaza, Alejandro Mínguez, Guillermo Bastida, Remedios Marqués, Pilar Nos, Jose Luis Poveda, Inés Moret-Tatay
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract usually characterized by diarrhea, rectal bleeding, and abdominal pain. IBD includes Crohn's disease and ulcerative colitis as the main entities. IBD is a debilitating condition that can lead to life-threatening complications, involving possible malignancy and surgery. The available therapies aim to achieve long-term remission and prevent disease progression. Biologics are bioengineered therapeutic drugs that mainly target proteins...
March 27, 2024: International Journal of Molecular Sciences
#12
EDITORIAL
Massimiliano Gasparrini, Luca Mazzoni
Inflammatory bowel diseases (IBD) comprise chronic debilitating inflammatory disorders that can affect different parts of the gastrointestinal tract and are commonly correlated to two main diseases: Crohn's disease (CD) and ulcerative colitis (UC) [...].
March 22, 2024: International Journal of Molecular Sciences
#13
JOURNAL ARTICLE
Stanko Petrović, Dino Tarabar, Danica Ćujić, Dusica Stamenkovic, Marijana Petrović, Nemanja Rančić, Vesna Subota, Nenad Perišić, Mihailo Bezmarević
Iron deficiency (IDA) and chronic disease (ACD) anemia are complications of inflammatory bowel diseases (IBDs). Therapeutic modalities in remission and active IBD depend on the type of anemia. This study evaluated the link between hepcidin-25, proinflammatory cytokines, and platelet activation markers as biomarkers of anemia and inflammation in active IBD and remission. This prospective observational study included 62 patients with IBD (49 with ulcerative colitis and 13 with Crohn's) and anemia. Patients were divided into Group I (no or minimal endoscopic signs of disease activity and IDA), Group II (moderate and major endoscopic signs of disease activity and mild ACD), and Control group (10 patients with IBD in remission, without anemia)...
March 22, 2024: International Journal of Molecular Sciences
#14
JOURNAL ARTICLE
Bruna Rošić Despalatović, Marija Babić, Andre Bratanić, Ante Tonkić, Žarko Ardalić, Katarina Vilović
Background: Crohn's disease (CD) and ulcerative colitis (UC) are well-defined phenotypes of chronic inflammatory bowel diseases (IBDs). A mechanism of inflammation in these diseases is partially controlled by the intestinal dendritic cell (DC). In this study, we observed a mature CD83+ DC in colonic bioptic samples, and its correlation with disease phenotype and activity. Methods: The study included 219 subjects: 100 with UC, 44 with CD and 75 healthy subjects. Colonic biopsy specimens were incubated with the primary antibody Anti-CD83...
April 3, 2024: Journal of Clinical Medicine
#15
JOURNAL ARTICLE
Livia Lontai, Lívia Priyanka Elek, Fruzsina Balogh, Dorottya Angyal, Péter Pajkossy, Lorant Gonczi, Peter L Lakatos, Ákos Iliás
Background: Inflammatory bowel diseases (IBDs) are chronic conditions that negatively affect the patient's quality of life. With the spread of the biopsychosocial model, the role of mental health in the activity and course of inflammatory bowel disease is becoming more and more recognized. Our study aimed to assess the prevalence of anxiety and depression in IBD patients in our tertiary referral center and determine the predictive factors of these mental conditions. Methods: A total of 117 patients were included consecutively between 1 December 2021 and 28 February 2022...
March 29, 2024: Journal of Clinical Medicine
#16
JOURNAL ARTICLE
Marta Vernero, Cristina Bezzio, Davide G Ribaldone, Flavio A Caprioli, Massimo C Fantini, Stefano Festa, Fabio S Macaluso, Ambrogio Orlando, Daniela Pugliese, Sara Renna, Antonio Rispo, Edoardo V Savarino, Angela Variola, Simone Saibeni
(1) Background : Inflammatory bowel disease (IBD) is frequently associated to other immune-mediated inflammatory diseases (IMIDs). This study aims at assessing physicians' awareness of the issue and the current status of IMID management. (2) Methods : A web-based survey was distributed to all 567 physicians affiliated to IG-IBD. (3) Results : A total of 249 (43.9%) physicians completed the survey. Over 90% of the responding physicians were gastroenterology specialists, primarily working in public hospitals...
March 23, 2024: Journal of Clinical Medicine
#17
REVIEW
Lingling Kan, Ziwen Zheng, Wanyue Fu, Yan Ma, Wanni Wang, Haisheng Qian, Lingling Xu
Inflammatory bowel disease (IBD) is a type of chronic recurrent inflammation disease that mainly includes Crohn's disease and ulcerative colitis. Currently, the treatments for IBD remain highly challenging, with clinical treatment drugs showing limited efficacy and adverse side effects. Thus, developing drug candidates with comprehensive therapeutic effects, high efficiency, and low toxicity is urgently needed. Recently, micro/nanomaterials have attracted considerable interest because of their bioavailability, multitarget and efficient effects on IBD...
April 10, 2024: Journal of Controlled Release
#18
JOURNAL ARTICLE
Pascal Petit, Ariane Leroyer, Sylvain Chamot, Mathurin Fumery, Vincent Bonneterre
BACKGROUND AND AIMS: Epidemiological data regarding inflammatory bowel disease (IBD) are lacking, in particular for occupationally exposed populations. We investigated whether, among the entire French farm manager (FM) workforce, certain agricultural activities are more strongly associated with IBD than others. METHODS: Nationwide population-based insurance claims and electronic health records from all FMs that worked at least once over the period 2002-2016 were used (n=1088561, 69% males)...
April 12, 2024: Journal of Crohn's & Colitis
#19
JOURNAL ARTICLE
Mustafa Mohamedrashed, Mayur Garg, Anuj Bohra
No abstract text is available yet for this article.
April 12, 2024: Journal of Crohn's & Colitis
#20
JOURNAL ARTICLE
Jianxia Ma, Ke Wang, Jun Wang, Qinlian Zeng, Kangwei Liu, Songbai Zheng, Yuanwen Chen, Jianfeng Yao
OBJECTIVE: The fecal microbiota was studied in patients with inflammatory bowel disease (IBD), and the characteristics of gut microbiota were compared among patients with different subtypes and stages of IBD, aiming to identify the gut microbiota associated with IBD. METHODS: Fecal samples were collected from 41 IBD patients (18 patients with ulcerative colitis [UC] and 23 patients with Crohn's disease [CD]) in the Department of Gastroenterology of East China Hospital, Fudan University between January 2021 and January 2022...
2024: International Journal of General Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
